The therapeutic efficacy of ATRA in classical APL stems from its direct binding to the RARA moiety of PML-RARA, inducing conformational changes that facilitate co-repressor complex dissociation and co-activator recruitment, thereby reactivating the RARA transcriptional network. Here, RARA is linked to acute promyelocytic leukemia.